불안장애 및 우울증 치료 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of anxiety disorders and depression treatment Market

The global anxiety disorders and depression treatment market size was valued at USD 16.18 billion in 2025 and is projected to grow from USD 16.99 billion in 2026 to USD 25.02 billion by 2034, registering a CAGR of 4.96% during 2026-2034. North America dominated the global market with a 52.24% share in 2025, supported by the high prevalence of anxiety and depression, established healthcare infrastructure, strong pharmaceutical research, and frequent introduction of innovative therapies.

The market includes medications used to manage anxiety disorders and depressive conditions, with major drug classes including antidepressants, anxiolytics, anticonvulsants, noradrenergic agents, and atypical antipsychotics. Growing awareness of mental health, increasing disease burden, expansion of clinical research, and development of novel therapies are supporting market growth. Pharmaceutical companies are also increasing collaborations and research programs to address unmet treatment needs and improve patient access to effective therapies.

Market Definition and Scope

The anxiety and depression treatment market comprises pharmaceutical products used for the management of anxiety disorders and depressive conditions. The market is segmented by drug class, indication, and distribution channel. Key indications include anxiety and depression, while major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

Market Dynamics

Drivers

The increasing prevalence and economic burden of mental health disorders are major factors supporting market growth. Anxiety and depression affect populations across age groups and can create substantial financial and social costs. Growing recognition of the importance of timely diagnosis and treatment is encouraging healthcare providers and governments to expand mental health services.

A strong drug pipeline is another important growth factor. Pharmaceutical companies are developing new molecules, combination therapies, and innovative treatment approaches for major depressive disorder and other psychiatric conditions. Clinical trials and regulatory submissions are increasing the availability of potential treatment options.

Trends

Robust research and development is a major trend in the market. Companies are investing in strategic collaborations, clinical trials, and novel therapies designed to improve treatment outcomes. Digital healthcare and teletherapy also gained importance during the pandemic, supporting broader access to mental healthcare consultations and treatment services.

Restraints

Adverse effects associated with anxiety and depression medications can limit their adoption. Potential effects such as dizziness, nausea, weight changes, and blurred vision can affect treatment adherence. In addition, a substantial gap exists between the number of people requiring mental healthcare and those receiving appropriate treatment, particularly in developing economies.

Impact of COVID-19

The COVID-19 pandemic had a positive impact on demand for anxiety and depression treatments. Increased financial, social, and emotional pressures contributed to higher levels of stress, anxiety, and depression. Telemedicine and teletherapy services expanded significantly, while pharmaceutical companies strengthened supply chains to maintain medicine availability. The pandemic also increased awareness of mental health and the importance of accessible treatment.

Segmentation Analysis

By Drug Class

The market is segmented into antidepressants, anxiolytics, anticonvulsants, noradrenergic agents, and atypical antipsychotics. Antidepressants accounted for the largest market share, supported by their widespread use for depressive disorders and continued product development. Increasing clinical trials and approvals are expected to support this segment.

By Indication

The market is divided into anxiety and depression. Anxiety disorders represent an important demand area because of their widespread prevalence, including generalized anxiety disorder, social anxiety disorder, and phobias. Depression, including major depressive disorder, also represents a substantial treatment population and continues to drive demand for effective pharmaceutical therapies.

By Distribution Channel

Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies held the leading share, supported by prescription-based treatment and patient visits. Retail pharmacies benefit from regular medication requirements, while online pharmacies are expected to expand as digital healthcare adoption increases.

Regional Insights

North America

North America dominated the market with a 52.24% share in 2025. High prevalence of anxiety and depression, advanced healthcare infrastructure, pharmaceutical innovation, and the presence of major companies support regional growth.

Europe

Europe held the second-largest position, supported by investments in antidepressant research and development and increasing demand for treatments targeting anxiety and depressive disorders.

Asia Pacific

Asia Pacific is expected to witness the fastest growth during the forecast period. Increasing awareness of mental health, rising demand for antidepressants, expanding healthcare infrastructure, and the growing incidence of depressive disorders are supporting regional opportunities.

Latin America, Middle East & Africa

Latin America and the Middle East & Africa are expected to experience comparatively slower growth because of differences in treatment access, healthcare infrastructure, product availability, and awareness of mental health conditions.

Competitive Landscape

Key companies operating in the market include Pfizer Inc., H. Lundbeck A/S, GlaxoSmithKline plc, Merck & Co. Inc., Eli Lilly and Company, Johnson & Johnson, AstraZeneca, and Bristol-Myers Squibb. Companies are focusing on clinical development, product launches, strategic collaborations, and innovative treatment approaches to strengthen their market presence.

Report Coverage

The anxiety disorders and depression treatment market report covers market size and forecast, drug classes, indications, distribution channels, regional analysis, market trends, growth drivers, restraints, competitive landscape, key companies, and industry developments. The report also evaluates developments in clinical research and innovative therapies influencing the treatment landscape.

Conclusion

The global anxiety disorders and depression treatment market is projected to increase from USD 16.18 billion in 2025 to USD 16.99 billion in 2026 and reach USD 25.02 billion by 2034, at a CAGR of 4.96%. Increasing prevalence of mental health disorders, rising awareness, expanding clinical research, strong drug pipelines, and improved access to treatment are supporting market development. North America remains the leading regional market, while Asia Pacific is expected to experience strong growth. Continued pharmaceutical innovation, collaborations, and expansion of healthcare access are expected to influence the market through 2034.

Unit Value (USD Billion)

Segmentation Drug Class; Indication; Distribution Channel; and Region

By Drug Class

• Antidepressants
• Anxiolytics
• Anticonvulsants
• Noradrenergic Agents
• Atypical Antipsychotics

By Indication

• Anxiety
• Depression

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America (Drug Class; Indication; Distribution Channel)
  • USA (By Indication)
  • Canada (By Indication)
• Europe (Drug Class; Indication; Distribution Channel)
  • The U.K. (By Indication)
  • Germany (By Indication)
  • France (By Indication)
  • Italy (By Indication)
  • Spain (By Indication)
  • Scandinavia (By Indication)
  • Rest of Europe (By Indication)
• Asia Pacific (Drug Class; Indication; Distribution Channel)
  • Japan (By Indication)
  • China (By Indication)
  • India (By Indication)
  • Australia (By Indication)
  • Southeast Asia (By Indication)
  • Rest of Asia Pacific (By Indication)
• Latin America (Drug Class; Indication; Distribution Channel)
  • Brazil (By Indication)
  • Mexico (By Indication)
  • Rest of Latin America (By Indication)
• The Middle East & Africa (Drug Class; Indication; Distribution Channel)
  • GCC (By Indication)
  • South Africa (By Indication)
  • Rest of Middle East & Africa (By Indication)

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Market Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Anxiety & Depression -Key Regions/Country
• 4.2. New Product Launch
• 4.3. Pipeline Analysis
• 4.4. Impact of COVID-19 on the Anxiety Disorders and Depression Treatment Market
• 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships

5. Global Anxiety Disorders and Depression Treatment Market Analysis, Insights and Forecast, 2021-2031

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Antidepressants
  • 5.2.2. Anxiolytics
  • 5.2.3. Anticonvulsants
  • 5.2.4. Noradrenergic Agents
  • 5.2.5. Atypical Antipsychotics
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Anxiety
  • 5.3.2. Depression
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacy
  • 5.4.2. Retail Pharmacy
  • 5.4.3. Online Pharmacy
• 5.5. Market Analysis, Insights and Forecast - By Geography
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Anxiety Disorders and Depression Treatment Market Analysis, Insights and Forecast, 2021-2031

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Drug Class
  • 6.2.1. Antidepressants
  • 6.2.2. Anxiolytics
  • 6.2.3. Anticonvulsants
  • 6.2.4. Noradrenergic Agents
  • 6.2.5. Atypical Antipsychotics
• 6.3. Market Analysis, Insights and Forecast - By Indication
  • 6.3.1. Anxiety
  • 6.3.2. Depression
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacy
  • 6.4.2. Retail Pharmacy
  • 6.4.3. Online Pharmacy
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
    • 6.5.1.1. By Indication
      • 6.5.1.1.1. Anxiety
      • 6.5.1.1.2. Depression
  • 6.5.2. Canada
    • 6.5.2.1. By Indication
      • 6.5.2.1.1. Anxiety
      • 6.5.2.1.2. Depression

7. Europe Anxiety Disorders and Depression Treatment Market Analysis, Insights and Forecast, 2021-2031

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Drug Class
  • 7.2.1. Antidepressants
  • 7.2.2. Anxiolytics
  • 7.2.3. Anticonvulsants
  • 7.2.4. Noradrenergic Agents
  • 7.2.5. Atypical Antipsychotics
• 7.3. Market Analysis, Insights and Forecast - By Indication
  • 7.3.1. Anxiety
  • 7.3.2. Depression
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. Online Pharmacy
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
    • 7.5.1.1. By Indication
      • 7.5.1.1.1. Anxiety
      • 7.5.1.1.2. Depression
  • 7.5.2. Germany
    • 7.5.2.1. By Indication
      • 7.5.2.1.1. Anxiety
      • 7.5.2.1.2. Depression
  • 7.5.3. France
    • 7.5.3.1. By Indication
      • 7.5.3.1.1. Anxiety
      • 7.5.3.1.2. Depression
  • 7.5.4. Spain
    • 7.5.4.1. By Indication
      • 7.5.4.1.1. Anxiety
      • 7.5.4.1.2. Depression
  • 7.5.5. Italy
    • 7.5.5.1. By Indication
      • 7.5.5.1.1. Anxiety
      • 7.5.5.1.2. Depression
  • 7.5.6. Scandinavia
    • 7.5.6.1. By Indication
      • 7.5.6.1.1. Anxiety
      • 7.5.6.1.2. Depression
  • 7.5.7. Rest of Europe
    • 7.5.7.1. By Indication
      • 7.5.7.1.1. Anxiety
      • 7.5.7.1.2. Depression

8. Asia Pacific Anxiety Disorders and Depression Treatment Market Analysis, Insights and Forecast, 2021-2031

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Drug Class
  • 8.2.1. Antidepressants
  • 8.2.2. Anxiolytics
  • 8.2.3. Anticonvulsants
  • 8.2.4. Noradrenergic Agents
  • 8.2.5. Atypical Antipsychotics
• 8.3. Market Analysis, Insights and Forecast - By Indication
  • 8.3.1. Anxiety
  • 8.3.2. Depression
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Online Pharmacy
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Japan
    • 8.5.1.1. By Indication
      • 8.5.1.1.1. Anxiety
      • 8.5.1.1.2. Depression
  • 8.5.2. China
    • 8.5.2.1. By Indication
      • 8.5.2.1.1. Anxiety
      • 8.5.2.1.2. Depression
  • 8.5.3. India
    • 8.5.3.1. By Indication
      • 8.5.3.1.1. Anxiety
      • 8.5.3.1.2. Depression
  • 8.5.4. Australia
    • 8.5.4.1. By Indication
      • 8.5.4.1.1. Anxiety
      • 8.5.4.1.2. Depression
  • 8.5.5. Southeast Asia
    • 8.5.5.1. By Indication
      • 8.5.5.1.1. Anxiety
      • 8.5.5.1.2. Depression
  • 8.5.6. Rest of Asia Pacific
    • 8.5.6.1. By Indication
      • 8.5.6.1.1. Anxiety
      • 8.5.6.1.2. Depression

9. Latin America Anxiety Disorders and Depression Treatment Market Analysis, Insights and Forecast, 2021-2031

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Drug Class
  • 9.2.1. Antidepressants
  • 9.2.2. Anxiolytics
  • 9.2.3. Anticonvulsants
  • 9.2.4. Noradrenergic Agents
  • 9.2.5. Atypical Antipsychotics
• 9.3. Market Analysis, Insights and Forecast - By Indication
  • 9.3.1. Anxiety
  • 9.3.2. Depression
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Retail Pharmacy
  • 9.4.3. Online Pharmacy
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
    • 9.5.1.1. By Indication
      • 9.5.1.1.1. Anxiety
      • 9.5.1.1.2. Depression
  • 9.5.2. Mexico
    • 9.5.2.1. By Indication
      • 9.5.2.1.1. Anxiety
      • 9.5.2.1.2. Depression
  • 9.5.3. Rest of Latin America
    • 9.5.3.1. By Indication
      • 9.5.3.1.1. Anxiety
      • 9.5.3.1.2. Depression

10. Middle East & Africa Anxiety Disorders and Depression Treatment Market Analysis, Insights and Forecast, 2021-2031

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Drug Class
  • 10.2.1. Antidepressants
  • 10.2.2. Anxiolytics
  • 10.2.3. Anticonvulsants
  • 10.2.4. Noradrenergic Agents
  • 10.2.5. Atypical Antipsychotics
• 10.3. Market Analysis, Insights and Forecast - By Indication
  • 10.3.1. Anxiety
  • 10.3.2. Depression
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy
  • 10.4.3. Online Pharmacy
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
    • 10.5.1.1. By Indication
      • 10.5.1.1.1. Anxiety
      • 10.5.1.1.2. Depression
  • 10.5.2. South Africa
    • 10.5.2.1. By Indication
      • 10.5.2.1.1. Anxiety
      • 10.5.2.1.2. Depression
  • 10.5.3. Rest of Middle East & Africa
    • 10.5.3.1. By Indication
      • 10.5.3.1.1. Anxiety
      • 10.5.3.1.2. Depression

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Company Profiles
  • 11.3.1. Pfizer Inc.
    • 11.3.1.1. Overview,
    • 11.3.1.2. Products,
    • 11.3.1.3. SWOT Analysis,
    • 11.3.1.4. Recent Developments,
    • 11.3.1.5. Strategies,
    • 11.3.1.6. Financials (Based on Availability)
  • 11.3.2. H. Lundbeck A/S
    • 11.3.2.1. Overview,
    • 11.3.2.2. Products,
    • 11.3.2.3. SWOT Analysis,
    • 11.3.2.4. Recent Developments,
    • 11.3.2.5. Strategies,
    • 11.3.2.6. Financials (Based on Availability)
  • 11.3.3. GlaxoSmithKline plc
    • 11.3.3.1. Overview,
    • 11.3.3.2. Products,
    • 11.3.3.3. SWOT Analysis,
    • 11.3.3.4. Recent Developments,
    • 11.3.3.5. Strategies,
    • 11.3.3.6. Financials (Based on Availability)
  • 11.3.4. Merck & Co. Inc.
    • 11.3.4.1. Overview,
    • 11.3.4.2. Products,
    • 11.3.4.3. SWOT Analysis,
    • 11.3.4.4. Recent Developments,
    • 11.3.4.5. Strategies,
    • 11.3.4.6. Financials (Based on Availability)
  • 11.3.5. Eli Lilly and Company
    • 11.3.5.1. Overview,
    • 11.3.5.2. Products,
    • 11.3.5.3. SWOT Analysis,
    • 11.3.5.4. Recent Developments,
    • 11.3.5.5. Strategies,
    • 11.3.5.6. Financials (Based on Availability)
  • 11.3.6. Johnson & Johnson
    • 11.3.6.1. Overview,
    • 11.3.6.2. Products,
    • 11.3.6.3. SWOT Analysis,
    • 11.3.6.4. Recent Developments,
    • 11.3.6.5. Strategies,
    • 11.3.6.6. Financials (Based on Availability)
  • 11.3.7. AztraZeneca
    • 11.3.7.1. Overview,
    • 11.3.7.2. Products,
    • 11.3.7.3. SWOT Analysis,
    • 11.3.7.4. Recent Developments,
    • 11.3.7.5. Strategies,
    • 11.3.7.6. Financials (Based on Availability)
  • 11.3.8. Bristol-Myers Squibb
    • 11.3.8.1. Overview,
    • 11.3.8.2. Products,
    • 11.3.8.3. SWOT Analysis,
    • 11.3.8.4. Recent Developments,
    • 11.3.8.5. Strategies,
    • 11.3.8.6. Financials (Based on Availability)
  • 11.3.9. Other Prominent Players
    • 11.3.9.1. Overview,
    • 11.3.9.2. Products,
    • 11.3.9.3. SWOT Analysis,
    • 11.3.9.4. Recent Developments,
    • 11.3.9.5. Strategies,
    • 11.3.9.6. Financials (Based on Availability)

12. Strategic Recommendations